France Weighs Return To Lockdown As Russia Refuses Despite Spike In COVID-19 Cases, Deaths: Live Updates
Mirati To Launch $700M Public Offering; Shares Fall After-Hours
Good Entry Point for Gilead Sciences (GILD)? Not Just Yet, Says Analyst
Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea
South Korea pharma Celltrion’s Covid test gets U.S. emergency use authorization
Moderna Inks Qatar Supply Deal For Covid-19 Vaccine
PhaseBio Plunges 10% As Covid-19 Trial Called Off; Street Stays Bullish
Moderna nears COVID-19 vaccine finish line as it wraps up study enrolment
Convalescent plasma misses the mark in phase 2 trial
Weekly Market Outlook: BOC, BOJ, ECB and corporate earnings in focus
OrganiGram Pays Next $2.5M To Cannabis Biotech Firm Hyasynth
NextGen Soars 8% On Earnings, Reinstates Guidance
J&J Prepares To Restart US Covid-19 Vaccine Trial Recruitment
AstraZeneca Gets FDA Nod To Resume US Covid-19 Trial
A Novavax Bull Cuts His Price Target, Citing ‘Challenged National Sentiment' Towards COVID-19 Vaccination
AstraZeneca, Oxford allowed to resume Covid-19 vaccine trial in U.S. – WSJ
Managing and Mismanaging the Covid Shock
Global Markets Rise Despite Fading Odds Of Stimulus Deal
FDA Approves Gilead's Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn't Work
Gilead’s Remdesivir Wins FDA’s First COVID-19 Drug Approval
Gilead’s remdesivir finally gets US approval
Gilead’s Covid-19 Remdesivir Drug Scores FDA Approval; Shares Surge
FDA Grants Full Approval to Remdesivir for Covid-19
AT&T Surprises With 3Q Sales Win; Shares Gain 5%
Roche to co-develop remdesivir rival in partnership with Atea
AstraZeneca Covid-19 Brazil Trial To Continue After Volunteer Dies - Report
Headache for Zosano as FDA turns down migraine patch
Brightcove Pops 12% After Record Sales Quarter; Street Says Buy
Lilly hires external adviser for Covid-19 drug plant problems
Tracking the SARS-CoV-2 virus with genome sequencing